CJC-1295 vs MK-677

Overview

CJC-1295 and MK-677 (ibutamoren) both increase growth hormone and IGF-1 levels but through different mechanisms. CJC-1295 is a GHRH analog requiring injection, while MK-677 is an oral ghrelin receptor agonist. Neither is FDA-approved, but MK-677 has more extensive clinical trial data.

Key Facts

Aspect	CJC-1295	MK-677
Class	GHRH analog	GH secretagogue
Type	Peptide (injectable)	Small molecule (oral)
Target	GHRH receptor	GHS-R1a (ghrelin receptor)
FDA Status	Not approved	Not approved
Variants	No DAC / DAC	Single form

Mechanism Comparison

Aspect	CJC-1295	MK-677
Receptor	GHRH-R	GHS-R1a
GH Release	Pulsatile (no DAC) or sustained (DAC)	Sustained
IGF-1 Effect	Increases	Increases significantly
Appetite	Minimal	Strongly increases
Cortisol	Minimal	Variable

CJC-1295 Variants

Variant	Half-life	GH Pattern
No DAC (Mod GRF 1-29)	~30 minutes	Pulsatile
With DAC	6-8 days	Sustained elevation

Evidence Comparison

Aspect	CJC-1295	MK-677
Human Trials	Limited (Phase 2)	Extensive
Publication Quality	Low-moderate	Moderate-high
Development Status	Abandoned	Abandoned (no approval)
Regulatory History	Never reviewed	Failed to achieve approval

MK-677 Clinical Program

Despite extensive trials, MK-677 never achieved approval:

• Hip fracture: No functional benefit
• Obesity: Appetite counterproductive
• Elderly: No clear benefit
• Metabolic concerns persistent

GH and IGF-1 Effects

Parameter	CJC-1295 No DAC	CJC-1295 DAC	MK-677
GH Pattern	Pulsatile	Sustained	Sustained
IGF-1 Increase	Moderate	Significant	Significant
Duration	2-3 hours	Days	24 hours
Physiological	More	Less	Less

Side Effect Comparison

CJC-1295

Effect	No DAC	DAC
Injection site	Common	Common
Flushing	Occasional	Occasional
Water retention	Mild	More
Appetite	Minimal	Minimal

MK-677

Effect	Frequency	Notes
Appetite increase	Very common	Major effect
Water retention	Very common	Significant edema
Lethargy	Common	Morning fatigue
Hyperglycemia	Common	Metabolic concern
Muscle pain	Common	GH-related

Metabolic Impact

Effect	CJC-1295	MK-677
Appetite	Minimal	Strong increase
Glucose tolerance	Minimal	Worsens
Insulin sensitivity	Preserved	Decreases
Body composition	Potentially favorable	Complicated by appetite

Administration

Aspect	CJC-1295 No DAC	CJC-1295 DAC	MK-677
Route	Injection	Injection	Oral
Convenience	Low	Moderate	High

Regulatory Status

Aspect	CJC-1295	MK-677
FDA Approval	No	No
Development	Limited	Extensive (failed)
Availability	Research chemical	Research chemical
WADA Status	Prohibited	Prohibited
Quality Control	None	None

Combination Considerations

CJC-1295 (no DAC) is often combined with GHRPs due to different receptors:

Combination	Rationale
CJC-1295 + Ipamorelin	Common, different receptors
CJC-1295 + GHRP-2	Maximum GH pulse
MK-677 alone	Already sustained; no GHRP needed

MK-677’s long half-life makes combination with GHRPs redundant.

Key Differences

Factor	CJC-1295	MK-677
Administration	Injectable	Oral
Mechanism	GHRH-R	GHS-R1a
GH Pattern	Pulsatile (no DAC)	Sustained
Appetite	Minimal	Strong increase
Glucose	Minimal	Worsens
Trial Data	Limited	Extensive
Why Not Approved	Not pursued	Failed trials

Practical Considerations

Choose CJC-1295 (No DAC) When:

• Pulsatile GH preferred
• Combining with GHRPs
• Avoiding appetite increase important
• Glucose concerns

Choose MK-677 When:

• Oral dosing essential
• Appetite stimulation desired
• Simple protocol preferred
• Understanding metabolic risks

Summary

• CJC-1295 is a GHRH analog that can create pulsatile or sustained GH release depending on variant
• MK-677 is an oral option with sustained GH/IGF-1 elevation but significant metabolic effects
• MK-677’s appetite and glucose effects are major limitations
• CJC-1295 (no DAC) creates more physiological GH patterns
• Neither is FDA-approved; both are research chemicals only
• Both are prohibited in sport

---

This comparison is for educational purposes only. Neither compound is approved for human use. Products sold are unregulated research chemicals with uncertain quality and safety.